ARN19702
Avis client
Based on 1 Customer Validation
ARN19702 is a selective, orally active, reversible, and brain-penetrant N-acylethanolamine acid amidase (NAAA) inhibitor with an IC50 of 230 nM for human NAAA. ARN19702 has pain relief effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.69%
- CAS No.: 1971937-18-4
- Formule: C21H22FN3O3S2
- Masse moléculaire:447.55
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
IC50 & Target
IC50: 230 nM (human NAAA)[2]
In Vivo
ARN19702 (3-10 mg/kg; po; daily; for 7 consecutive days) reduces nociception associated with Paclitaxel-induced neuropathy without development of subacute antinociceptive tolerance in male rats[1].
In male mice, ARN19702 (0.1-30 mg/kg; po) attenuates in a dose-dependent manner the spontaneous nocifensive response elicited by intraplantar formalin injection and the hypersensitivity caused by intraplantar carrageenan injection, paw incision, or sciatic nerve ligation[1].
. ARN19702 (3-10 mg/kg; po) produces remarkable protective effects against multiple sclerosis in mice[2].
Pharmacokinetic properties of ARN19702 in mice
In male mice, ARN19702 (0.1-30 mg/kg; po) attenuates in a dose-dependent manner the spontaneous nocifensive response elicited by intraplantar formalin injection and the hypersensitivity caused by intraplantar carrageenan injection, paw incision, or sciatic nerve ligation[1].
. ARN19702 (3-10 mg/kg; po) produces remarkable protective effects against multiple sclerosis in mice[2].
Pharmacokinetic properties of ARN19702 in mice
| 3 mg/kg,i.v | 3 mg/kg, p.o. | |
| Cmax (ng/mL) | 1660±166 | 613±68 |
| Tmax (min) | (5.0) | 30 |
| CL (mL/min/Kg) | 33.2±1.6 | 49±8 |
| t1/2 (min) | 73.9±3.7 | 104±16 |
| AUCplasma (h×ng/mL) | 1366.8±68.3 | 988±157 |
| AUCbrain (h×ng/mL) | 404.3±109.1 | 181±28 |
| F (%) | - | 72±11 |